Prosensa re-starts drisapersen dosing amid analyst skepticism
This article was originally published in Scrip
Executive Summary
Prosensa has restarted dosing patients with drisapersen, its Duchenne muscular dystrophy (DMD) drug candidate, which had been suspended following the failure of the Phase III DEMAND study last year, which led to GlaxoSmithKline returning rights to the drug in January. However, analysts remain skeptical of the Dutch biotech's chances of success.